The US Food and Drug Administration recently convened a panel of experts to examine a sensitive and increasingly urgent question: should antidepressants be prescribed to women suffering from depression during pregnancy?
To the surprise of many in the American medical community, the panel included not only US-based experts but also three international voices known for their critical views on psychiatric medication. Their inclusion sparked immediate controversy and foreshadowed the disagreements to come.
At the heart of the debate is a long-standing assumption in American medical practice: while antidepressants may carry some risk to the unborn child, the dangers of leaving maternal depression untreated are usually greater. Yet this mainstream position was strongly challenged. A majority of the panel appeared unconvinced that the benefits of antidepressant use in pregnancy clearly outweigh the potential risks.
